Single‐dose psilocybin superior to placebo for MDD in community setting
Major depressive disorder (MDD) affects about 300 million people worldwide. About one‐third of these have treatment‐resistant depression (TRD), commonly defined as a failure to respond to two antidepressants. Although these conditions represent a major public health problem, access to specialized treatments is limited.
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/pu.31520
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00